Merakris Therapeutics Announces FDA Clearance for Part 2 of its Phase II Multicenter Investigational New Drug Study of Dermacyte® Liquid Part 2 of the Phase II multicenter clinical study for the investigational wound care drug, Dermacyte® Amniotic Wound Care Liquid, will begin late 2024.

Negative Pressure Wound Therapy (NPWT) Devices Market to Surpass US$ 3,789.9 Million by 2030, Says Coherent Market Insights (CMI) Burlingame, Feb. 20, 2023 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global negative pressure wound therapy (NPWT) devices market is estimated to be valued at US$ 2,288.1 million...

Global Negative Pressure Wound Therapy (NPWT) Devices Market to Surpass US$ 4,318.7 Million by 2030, Says Coherent Market Insights (CMI) Seattle, Aug. 16, 2022 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global negative pressure wound therapy (NPWT) devices market is estimated to be valued at US$ 2,560.2 million in...

Merakris Therapeutics, Inc. Announces FDA Clearance for Dermacyte® Liquid Clinical Trial RESEARCH TRIANGLE PARK, N.C., May 25, 2021 (GLOBE NEWSWIRE) -- Merakris Therapeutics, Inc. (Merakris) announced that it has received U.S. Food and Drug Administration (FDA) clearance for a Phase II...